Brief: Akeso Says NMPA Accepted New Drug Application For Ebdarokimab Injection
24/08/2023 01:31
Aug 24 (Reuters) - Akeso Inc 9926.HK :
* NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED NEW DRUG
APPLICATION FOR EBDAROKIMAB INJECTION
Further company coverage: 9926.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akeso
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
HK-listed Akeso drops most in nearly three months on discounted share sale
Brief: Akeso To Place 20 Million New Shares At HK$97.76 Per Share
Factbox: Major drugmakers turn to China for licensing deals